Who Owns the Rules of the Wired Mind?
Imagine a product that reads your intentions before you act on them, transmits that data to a server farm you cannot locate, and requires a neurosurgeon to uninstall. Now imagine that product sitting in a regulatory gray zone where three separate federal agencies argue over jurisdiction while a fourth in Brussels drafts a framework that may not apply to it at all. That is not a hypothetical. That is the governance reality of brain-computer interfaces in 2025, and it is arriving faster than the rule books can be rewritten.
The accelerating commercialization of neurotechnology, driven in no small part by Neuralink's high-profile human trials and a broader surge of venture capital into companies like Synchron, Blackrock Neurotech, and Precision Neuroscience, has shoved an uncomfortable question to the front of the policy queue: who, exactly, is in charge of governing a device that sits at the intersection of medical implant, consumer electronics, and artificial intelligence data pipeline?
A Three-Agency Tangle and a Missing Rulebook
In the United States, the Food and Drug Administration has historically treated implantable neural devices as Class III medical devices, the highest risk category, requiring the most stringent premarket approval process. Neuralink received its Breakthrough Device Designation in 2023 and subsequently launched its PRIME study, enrolling patients with severe paralysis to test the N1 chip's ability to translate neural signals into computer commands. The FDA pathway worked as intended for that narrow therapeutic application. But the agency's framework begins to buckle the moment a device crosses from clinical treatment into cognitive enhancement, productivity augmentation, or even recreational use, territory that the existing Medical Device Amendments of 1976 were never designed to govern.
The Federal Trade Commission enters the picture the moment neural data becomes a commercial asset. Under existing law, the FTC's authority over "unfair or deceptive practices" could theoretically extend to a company that harvests thought-adjacent behavioral data and sells it to advertisers, but the commission has never been asked to define the precise boundary between biometric signal and consumer data in a neural context. Meanwhile, the Federal Communications Commission holds authority over the wireless transmission protocols that BCI devices use to communicate with external processors, adding a third bureaucratic layer with its own definitions, timelines, and lobbying constituencies.
"The fundamental problem is not that we lack smart regulators. It is that we have regulatory structures built for a world where the brain was not a product interface."
The Stakeholder Map Is Not Neutral
Understanding why governance frameworks move slowly requires mapping who benefits from delay. Device manufacturers operating in regulatory ambiguity face lower compliance costs, faster iteration cycles, and wider latitude in data use agreements. Investors in pre-regulatory markets enjoy higher potential returns precisely because undefined risk is priced as upside. Neuralink, which is privately held and has not disclosed the commercial data strategy for its neural interface platform beyond therapeutic applications, benefits from a period in which no formal standard defines what it must disclose, retain, or delete about its users' brain activity.
On the other side of that ledger sit groups whose interests are structurally underrepresented in early-stage regulatory conversations. Patients in clinical trials, predominantly people with ALS, spinal cord injuries, or locked-in syndrome, occupy a position of profound informational asymmetry. They are, by necessity, early adopters of technology whose long-term data implications have not been adjudicated. Disability rights organizations have been increasingly vocal about this dynamic, arguing that framing BCI governance primarily as a medical device question obscures the civil liberties dimensions of the technology. If a person's primary communication channel runs through a proprietary neural interface, what happens to their voice if the company goes bankrupt, gets acquired, or simply discontinues the product line?
Labor economists are beginning to raise a different set of concerns. If non-medical cognitive enhancement via BCI becomes commercially available within the next decade, as several companies including Neuralink have suggested is the long-term vision, the workplace implications could dwarf anything produced by smartphones or social media. An employee who can process information, draft responses, or operate machinery at enhanced neural speeds presents a genuine policy dilemma: does refusing the interface constitute a reasonable accommodation, or does it become a competitive liability that employers can legally factor into hiring decisions? No current labor law in any jurisdiction provides an answer.
The International Standards Race and Why It Matters More Than You Think
While domestic regulatory agencies debate jurisdiction, the international standards arena is where the longer-term governance architecture is actually being built, and the race to define those standards is intensely geopolitical. The International Electrotechnical Commission and the IEEE are both actively developing technical standards for neural interface safety, interoperability, and data formats. The European Union's AI Act, which came into full force in 2024, contains provisions that may apply to AI-driven signal decoding components of BCI systems, though the precise applicability to implanted devices remains contested among legal scholars in Berlin, Paris, and Brussels.
China, which has made neurotechnology a national strategic priority, is simultaneously developing its own standards framework through the Ministry of Industry and Information Technology. The concern among Western policy researchers is not hypothetical: if Chinese and American BCI standards diverge significantly at the technical layer, the result could be a fragmented global ecosystem in which devices, data formats, and privacy protections are incompatible across borders, a neural equivalent of the 5G standards war, with considerably more intimate stakes.
The "Neural Data" Problem: A Category Without a Law
Perhaps the most urgent unresolved governance question is definitional: what legal category does neural data belong to? Under HIPAA, health data generated within a clinical context has defined protections. Under GDPR, biometric data receives special category status. But neural signals captured by a consumer-facing enhancement device, not used for diagnosis, not processed by a healthcare provider, and transmitted via a direct-to-consumer app, fall into a definitional no-man's-land that existing frameworks were not built to occupy.
Colorado, Minnesota, and Texas have each passed or introduced neurological data privacy legislation at the state level, recognizing that federal frameworks are not moving fast enough. These state laws vary significantly in scope, definition, and enforcement mechanism, creating a compliance patchwork that may actually impede the development of coherent national standards by allowing companies to forum-shop for the most permissive jurisdiction in which to domicile their data operations.
Neuralink's terms of service, like those of virtually every other company in the space, grant the company broad rights to use de-identified neural data for research and product development. Whether that data can be truly de-identified, given that neural firing patterns may be as individually unique as a fingerprint, is a question that neither the company nor any regulatory body has publicly answered with technical specificity.
What Good Governance Actually Looks Like
A cohesive governance framework for BCIs would need to accomplish several things simultaneously that current structures handle separately or not at all. It would need to track devices across their full lifecycle, from implantation through potential obsolescence and explantation, with clear liability assignments at each stage. It would need to define neural data as a distinct category with specific consent, storage, and transferability rules that cannot be waived by a terms-of-service click. It would need to establish international interoperability standards through diplomatic channels with the same urgency currently applied to semiconductor supply chains.
Several policy researchers advocate for a dedicated Neurotechnology Regulatory Office, housed within the FDA but with formal coordination mandates with the FTC, FCC, and relevant national security bodies, specifically to prevent the jurisdictional fragmentation that has allowed the current governance gap to persist. A 2024 report from the Neurorights Foundation proposed an analogous international body modeled loosely on the International Atomic Energy Agency, an independent agency with inspection authority and standard-setting power, calibrated to the specific dual-use risks of technology that can both restore human function and surveil human cognition.
None of these solutions are simple. All of them face opposition from industry actors who profit from the current ambiguity. But the governance window is narrow. Once commercial BCI ecosystems develop network effects comparable to what smartphones achieved between 2008 and 2015, the structural power of incumbents will make retroactive regulation enormously difficult. The wired mind is coming. The question is not whether someone will write the rules. It is whether the people most affected by those rules will have any meaningful voice in drafting them.
